CAR-T

#allogeneic cell therapies #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #Haematology

New DDW Highlights podcast: 24 June 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  It’s been another busy week in the world of cell therapy, with the first… Read More

#News

#allogeneic cell therapies #Blood cancer #CAR-T #Cell and gene therapy #Cell therapy #Haematology

This week in drug discovery (17-21 June) 

News round-up for 17-21 June by DDW Senior Digital Content Editor Diana Spencer. It’s been another busy week in the world of cell therapy, with the first use of CAR-T therapy for stiff-person syndrome, a study debunking the risk of secondary cancers from CAR-T and a number of… Read More

#News

CAR-T therapy
#Autoimmune disease #CAR-T #Cell therapy #Kyverna Therapeutics #Neurology

First use of CAR-T therapy in patient with stiff-person syndrome

KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, has been used to treat a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS). The therapy was given as part of a named-patient use in Germany for critically ill individuals who fail conventional therapies. Read More

#News

Blood cancer
#Antibodies #Blood cancer #CAR-T #Cell therapy #Clinical trials #Events #Haematology

EHA2024: Industry shares latest drug research in blood cancers

A number of key findings in haematological malignancies were revealed at this year’s European Hematology Association (EHA) Congress, which was held in Madrid, Spain 13-16 June. Ibrutinib and talquetamab, Johnson & Johnson Johnson & Johnson shared clinical trial results for its drug candidates Talvey (talquetamab) and… Read More

#Cancer Research #News #Trending News

Trophy
#CAR-T #Cell therapy #Harvard Medical School #Nobel Prize

Prize honours pioneers in CAR-T cell therapy

The 2024 Warren Alpert Foundation Prize has been awarded to four scientists whose discoveries led to the creation of chimeric antigen receptor (CAR)-T cells. The award recipients are: Renier Brentjens, Katherine Anne Gioia Endowed Chair of Medicine and Deputy Director of Roswell Park Comprehensive Cancer Center… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Genetics / genomics

New DDW Highlights podcast: 17 June 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With a lead story on the restoration of congenital hearing loss following gene therapy,… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Gene therapy #Genetics / genomics

This week in drug discovery (10-14 June) 

News round-up for 10-14 June by DDW Senior Digital Content Editor Diana Spencer. With a lead story on the restoration of congenital hearing loss following gene therapy, the news highlights selection this week focuses on cell and gene therapies (CGT) and genetics, particularly some key progress in relation… Read More

#News

The European Medicines Agency in Amsterdam
#CAR-T #Cell therapy #European Commission #European Medicines Agency #Kite Pharma

EU relaxes safety monitoring of CAR-T therapies

The European Medicines Agency has approved a Type II variation to the Summary of Product Characteristics (SmPC) for Kite’s chimeric antigen receptor (CAR)-T cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel). The variation includes a reduction in daily hospital safety monitoring for patients following CAR-T cell therapy infusion from… Read More

#News #Regulatory

Woman using an asthma inhaler
#Asthma #CAR-T #Cell therapy #China #Preclinical investigations

Researchers push asthma into remission with one dose of CAR-T

A single dose of long-lived chimeric antigen receptor (CAR)-T therapy led to sustained repression of lung inflammation and alleviation of asthmatic symptoms in a new study. The paper, ‘A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice’, was… Read More

#Editor's Choice #News

Click chemistry
#Acepodia #Bioorthogonal chemistry #CAR-T #Cell therapy #Click chemistry #Oncology #Phase I trial

First use of click chemistry in CAR-T cell therapy shows promise

Acepodia has announced promising preliminary data from its Phase I dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin’s lymphoma (NHL). One out of five patients demonstrated complete response (CR) and three out… Read More

#Cancer Research #News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

CAR-T therapy
#Allogene Therapeutics #allogeneic cell therapies #CAR-T #Cell therapy #Funding #Oncology

$15 million CIRM grant supports allogeneic CAR-T in renal cell carcinoma

Allogene Therapeutics has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the development of ALLO-316, an AlloCAR T investigational product for the treatment of advanced or metastatic renal cell carcinoma (RCC). ALLO-316 targets CD70, which is highly expressed in RCC and is also… Read More

#Business & Investment #News